Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:513-519
Published online before print January 19, 2004, doi: 10.1161/01.CIR.0000109697.68832.5D
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/4/513    most recent
01.CIR.0000109697.68832.5Dv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, S. J.
Right arrow Articles by Baker, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, S. J.
Right arrow Articles by Baker, A. H.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Gene therapy
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology

(Circulation. 2004;109:513-519.)
© 2004 American Heart Association, Inc.


Basic Science Reports

Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors

Stephen J. White, DPhil*; Stuart A. Nicklin, PhD*; Hildegard Büning, PhD; M. Julia Brosnan, PhD; Kristen Leike; Emmanuel D. Papadakis, BSc; Michael Hallek, MD; Andrew H. Baker, PhD

From the Bristol Heart Institute, Bristol Royal Infirmary, Bristol (S.J.W., E.D.P.), and the Division of Cardiovascular and Medical Sciences, University of Glasgow (S.A.N., M.J.B., A.H.B.), UK; and the Laboratorium für Molekulare Biologie, Genzentrum, Ludwig-Maximilians Universität München (H.B., K.L., M.H.), the Medizinische Klinik III, Klinikum der Universität München (M.H.), and Gesellshaft für Strahelforschung (M.H.), Munich, Germany.

Correspondence to Dr A.H. Baker, Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G11 6NT UK. E-mail ab11f{at}clinmed.gla.ac.uk

Received May 9, 2003; de novo received August 12, 2003; revision received September 23, 2003; accepted September 25, 2003.

Background— Gene therapy offers an unprecedented opportunity to treat diverse pathologies. Adeno-associated virus (AAV) is a promising gene delivery vector for cardiovascular disease. However, AAV transduces the liver after systemic administration, reducing its usefulness for therapies targeted at other sites. Because vascular endothelial cells (ECs) are in contact with the bloodstream and are heterogeneous between organs, they represent an ideal target for site-specific delivery of biological agents.

Methods and Results— We isolated human venous EC-targeting peptides by phage display and genetically incorporated them into AAV capsids after amino acid 587. Peptide-modified AAVs transduced venous (but not arterial) ECs in vitro, whereas hepatocyte transduction was significantly lower than with native AAV. Intravenous infusion of engineered AAVs into mice produced reduced vector accumulation in liver measured 1 hour and 28 days after injection and delayed blood clearance rates compared with native AAV. Peptide-modified AAVs produced enhanced uptake of virions in the vena cava with selective transgene expression. Retargeting was dose dependent, and coinfusion of either heparin or free competing peptides indicated that uptake was principally independent of native AAV tropism and mediated via the peptide.

Conclusions— AAV tropism can be genetically engineered by use of phage display–derived peptides to generate vectors that are selective for the vasculature.


Key Words: gene therapy • endothelium • viruses • peptides




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
M. Trepel, C. A. Stoneham, H. Eleftherohorinou, N. D. Mazarakis, R. Pasqualini, W. Arap, and A. Hajitou
A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer
Mol. Cancer Ther., August 1, 2009; 8(8): 2383 - 2391.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
S. Daya and K. I. Berns
Gene Therapy Using Adeno-Associated Virus Vectors
Clin. Microbiol. Rev., October 1, 2008; 21(4): 583 - 593.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
D. Grimm, J. S. Lee, L. Wang, T. Desai, B. Akache, T. A. Storm, and M. A. Kay
In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses
J. Virol., June 15, 2008; 82(12): 5887 - 5911.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
L. Perabo, D. Goldnau, K. White, J. Endell, J. Boucas, S. Humme, L. M. Work, H. Janicki, M. Hallek, A. H. Baker, et al.
Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism
J. Virol., July 15, 2006; 80(14): 7265 - 7269.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. Vasileva, R. M. Linden, and R. Jessberger
Homologous recombination is required for AAV-mediated gene targeting
Nucleic Acids Res., July 5, 2006; 34(11): 3345 - 3360.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Liu and A. Deisseroth
Tumor vascular targeting therapy with viral vectors
Blood, April 15, 2006; 107(8): 3027 - 3033.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. J. Muller, B. Leuchs, S. T. Pleger, D. Grimm, W.-M. Franz, H. A. Katus, and J. A. Kleinschmidt
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors
Cardiovasc Res, April 1, 2006; 70(1): 70 - 78.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. A. Lochrie, G. P. Tatsuno, B. Christie, J. W. McDonnell, S. Zhou, R. Surosky, G. F. Pierce, and P. Colosi
Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Affect Transduction and Neutralization
J. Virol., January 15, 2006; 80(2): 821 - 834.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
H. Nakai, S. Fuess, T. A. Storm, S.-i. Muramatsu, Y. Nara, and M. A. Kay
Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice
J. Virol., January 1, 2005; 79(1): 214 - 224.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
A. H. Baker, A. Kritz, L. M. Work, and S. A. Nicklin
Cell-selective viral gene delivery vectors for the vasculature
Exp Physiol, January 1, 2005; 90(1): 27 - 31.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. Sharif, K. Daly, J. Crowley, and T. O'Brien
Current status of catheter- and stent-based gene therapy
Cardiovasc Res, November 1, 2004; 64(2): 208 - 216.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. G. Melo, M. Gnecchi, A. S. Pachori, D. Kong, K. Wang, X. Liu, R. E. Pratt, and V. J. Dzau
Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease
Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1761 - 1774.
[Abstract] [Full Text] [PDF]